NINDS tPA Trial — LLMpedia

NINDS tPA Trial
Name	NINDS tPA Trial
Date	1995
Location	United States
Investigators	National Institute of Neurological Disorders and Stroke
Intervention	Intravenous alteplase (tPA)
Condition	Acute ischemic stroke

Contents

NINDS tPA Trial

The NINDS tPA Trial was a landmark randomized clinical trial conducted by the National Institute of Neurological Disorders and Stroke in 1995 that evaluated intravenous tissue plasminogen activator (tPA, alteplase) for acute ischemic stroke. The trial influenced practice at institutions such as Johns Hopkins Hospital, Massachusetts General Hospital, and Mayo Clinic, and impacted guidelines from organizations including the American Heart Association and the American Stroke Association. The study's results reshaped acute stroke management in settings from Harvard Medical School affiliated centers to regional stroke systems in New York City and Chicago.

Background

The trial emerged against a backdrop of evolving stroke science involving figures and institutions like William Feinberg at Columbia University, investigators from UCLA, and collaborators from University of California, San Francisco. Prior efforts to recanalize occluded cerebral arteries invoked technologies and treatments associated with CT scan pioneers at Massachusetts General Hospital and thrombolysis research at Stanford University School of Medicine. Regulatory and policy contexts included oversight by the Food and Drug Administration and funding priorities from the National Institutes of Health and the Department of Health and Human Services. Influential contemporaneous trials and meetings at venues such as The Lancet symposia, American Academy of Neurology conferences, and workshops at Rockefeller University framed debates about risks, benefits, and trial ethics.

The multicenter, randomized, double‑blind, placebo‑controlled design recruited participants from academic centers including University of Pennsylvania, Yale School of Medicine, and University of Michigan. Investigators used neuroimaging from scanners produced by firms associated with research at Massachusetts General Hospital and coordinated data through networks reminiscent of trials from Duke University Medical Center. Enrollment criteria required clinical and radiographic diagnosis within a narrow therapeutic window similar to protocols discussed at meetings at NIH and ethical review by institutional review boards at Georgetown University Medical Center and University of California, San Diego. Outcome measures incorporated scales developed by researchers at Columbia University and assessments applied in multicenter stroke trials at Cleveland Clinic and Beth Israel Deaconess Medical Center. Statistical oversight involved collaborators from biostatistics departments at Johns Hopkins University and University of Washington.

The trial reported that patients treated with intravenous alteplase within three hours of symptom onset had significantly better functional outcomes at 90 days, a finding that reverberated across clinical centers such as Massachusetts General Hospital, Mayo Clinic, and Brigham and Women's Hospital. Data on symptomatic intracerebral hemorrhage generated intense scrutiny from experts at Stanford University School of Medicine and commentators in journals like The New England Journal of Medicine and JAMA. Subgroup analyses and secondary endpoints were debated at meetings hosted by American Heart Association and presented by investigators affiliated with University of California, Los Angeles and Northwestern University.

Following publication, professional organizations including the American Heart Association, American Stroke Association, and advisory panels involving the Food and Drug Administration incorporated the trial's findings into guideline recommendations for acute ischemic stroke care at tertiary centers such as Mount Sinai Hospital and trauma centers like Ben Taub Hospital. Regional stroke systems in cities including Los Angeles, Houston, and Philadelphia reorganized protocols to expedite door‑to‑needle times, drawing on implementation experiences from Kaiser Permanente facilities and academic programs at University of Pittsburgh Medical Center. The trial influenced training at institutions such as Harvard Medical School and fellowship curricula endorsed by the Accreditation Council for Graduate Medical Education.

Critics from academic centers including Oxford University and commentators in outlets like The Lancet and BMJ raised concerns about trial generalizability, selection criteria, and the balance of benefit versus hemorrhagic risk, topics debated at symposia attended by scholars from University of Toronto and McMaster University. Policy and legal discussions involved stakeholders such as the Food and Drug Administration and hospital risk management teams at Cleveland Clinic and NewYork-Presbyterian Hospital. Methodological critiques invoked standards established in trials at Duke University Medical Center and statistical practices from Johns Hopkins University biostatistics, prompting reanalyses and meta-analyses by consortia including investigators from Imperial College London and University College London.

The trial catalyzed numerous randomized trials and registries at institutions such as University of California, San Francisco, Karolinska Institute, and University of Heidelberg, and informed endovascular research at centers like The Montreal Neurological Institute and Cleveland Clinic. Longitudinal outcomes studies by groups at Columbia University and University of Pennsylvania and pooled analyses by consortia including European Stroke Organisation investigators refined patient selection, time windows, and adjunctive imaging protocols pioneered at Massachusetts General Hospital and Stanford University. The legacy endures in contemporary stroke systems of care spanning academic hospitals like Johns Hopkins Hospital and community networks managed by organizations such as Kaiser Permanente and continues to be cited in guidelines from the World Health Organization and policy discussions at the National Institutes of Health.

Category:Clinical trials